FEDERAL ELECTION COMMISSION

Sunshine Act Notice

CANCELLATION OF PREVIOUSLY ANNOUNCED MEETINGS:

Tuesday, December 4, 2001, 10 a.m.; meeting closed to the public.

Thursday, December 6, 2001, 10 a.m.; meeting open to the public.

DATE & TIME: Thursday, December 6, 2001 at 10 a.m.

PLACE: 999 E Street, NW, Washington, DC.

STATUS: This meeting will be closed to the public.

ITEMS TO BE DISCUSSED:

Compliance matters pursuant to 2 U.S.C. § 437g.

Audits conducted pursuant to 2 U.S.C. § 437g, § 438(b), and title 26, U.S.C.

Matters concerning participation in civil actions or proceedings or arbitration.

Internal personnel rules and procedures or matters affecting a particular employee.

PERSON TO CONTACT FOR INFORMATION: M. Ron Harris, Press Officer, telephone: (202) 694–1220.

Mary W. Dove,

Secretary of the Commission. [FR Doc. 01–29790 Filed 11–27–01; 2:44 pm] BILLING CODE 6715-01-M

FEDERAL HOUSING FINANCE BOARD

Sunshine Act Meeting

FEDERAL REGISTER CITATION OF PREVIOUS ANNOUNCEMENT: 66 FR 57967, November 19, 2001.

PREVIOUSLY ANNOUNCED TIME AND DATE OF THE MEETING: 10:00 a.m., Wednesday, November 28, 2001.

CANCELLATION OF THE MEETING: Notice is hereby given of the cancellation of the Board of Directors meeting scheduled for November 28, 2001.

CONTACT PERSON FOR MORE INFORMATION: Elaine L. Baker, Secretary to the Board, (202) 408–2837.

James L. Bothwell,

Managing Director. [FR Doc. 01–29713 Filed 11–26–01; 4:15 pm]

BILLING CODE 6725-01-P

FEDERAL HOUSING FINANCE BOARD

Sunshine Meeting; Notice Announcing an Open Meeting of the Board

TIME AND DATE: 10 A.M., Wednesday, December 5, 2001.

PLACE: Board Room, Second Floor, Federal Housing Finance Board, 1777 F Street, N.W., Washington, DC 20006.

STATUS: The entire meeting will be open to the public.

MATTERS TO BE CONSIDERED DURING PORTIONS OPEN TO THE PUBLIC:

- Final Rule: Unsecured Credit Limits for the Federal Home Loan Banks
- Waiver of Compliance with the Minimum Liquidity Requirements of § 932.8 and the Unsecured Credit Limits of § 932.9
- Proposed Rule: Amendments to the Affordable Housing Program

CONTACT PERSON FOR MORE INFORMATION: Elaine L. Baker, Secretary to the Board, (202) 408–2837.

James L. Bothwell,

Managing Director. [FR Doc. 01–29773 Filed 11–27–01; 2:08 pm] BILLING CODE 6725–01–P

FEDERAL RETIREMENT THRIFT INVESTMENT BOARD

Sunshine Act Meeting

TIME AND DATE: 10 a.m. (EST), December 10, 2001.

PLACE: 4th Floor, Conference Room 4506, 1250 H Street, NW., Washington, DC.

STATUS; Open.

MATTERS TO BE CONSIDERED:

- 1. Approval of the minutes of the November 13, 2001, Board member meeting.
- 2. Thrift Savings Plan activity report by the Executive Director.
- 3. Review of KPMG LLP audit reports:
 - (a) Thrift Savings Plan Billing Process at the Untied States Department of Agriculture, National Finance Center.
 - (b) Thrift Savings Plan Annuity Operations at the Metropolitan Life Insurance Company.

CONTACT PERSON FOR MORE INFORMATION:

Thomas J. Trabucco, Director, Office of External Affairs, (202) 942–1640.

Dated: November 27, 2001.

Elizabeth S. Woodruff,

Secretary to the Board, Federal Retirement Thrift Investment Board.

[FR Doc. 01–29822 Filed 11–29–01; 3:53 pm] BILLING CODE 6760–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Antiviral Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: Antiviral Drugs Advisory Committee.

General Function of the Meeting: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on December 12, 2001, from 8:15 a.m. to 5:15 p.m.

Location: Holiday Inn, Versailles Ballroom, 8120 Wisconsin Ave., Bethesda, MD.

Contact: Tara P. Turner, Center for Drug Evaluation and Research (HFD– 21), Food and Drug Administration, 5600 Fishers Lane (for express delivery 5630 Fishers Lane, rm. 1093), Rockville, MD 20857, 301–827–7001, e-mail: TurnerT@cder.fda.gov, or FDA Advisory Committee Information Line, 1–800– 741–8138 (301–443–0572 in the Washington, DC area), code 12531. Please call the Information Line for upto-date information on this meeting.

Agenda: The committee will be updated on the approval of biologics license application supplement 103949/ 5002, PEG–INTRON (peginterferon alfa-2b) powder for injection, Schering Corp., indicated for use alone or in combination with Rebetol (ribavirin, USP), for the treatment of chronic hepatitis C in patients with compensated liver disease who have not been previously treated with interferon alpha and are at least 18 years of age.

Procedure: On December 12, 2001, from 8:15 a.m. to 12:15 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by December 5, 2001. Oral presentations from the public will be scheduled between approximately 10 a.m. and 11 a.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before December 5, 2001, and submit a brief statement of the general nature of the evidence or arguments